Bivalirudin
- Generic Name
- Bivalirudin
- Brand Names
- Angiomax
- Drug Type
- Small Molecule
- Chemical Formula
- C98H138N24O33
- CAS Number
- 128270-60-0
- Unique Ingredient Identifier
- TN9BEX005G
- Background
Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and blood pressure.
- Indication
For treatment of heparin-induced thrombocytopenia and for the prevention of thrombosis. Bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention (PCI), in patients at moderate to high risk acute coronary syndromes due to unstable angina or non-ST segment elevation in whom a PCI is planned.
- Associated Conditions
- Thrombosis
Bivalirudin with Prolonged Infusion During PCI Versus Heparin After Fibrinolytic Therapy
- Conditions
- ST-segment Elevation Myocardial Infarction (STEMI)
- Interventions
- First Posted Date
- 2025-03-06
- Last Posted Date
- 2025-03-06
- Target Recruit Count
- 2400
- Registration Number
- NCT06861374
Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation
- Conditions
- Extracorporeal Membrane Oxygenation Complication
- Interventions
- First Posted Date
- 2024-02-23
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Xiaotong Hou
- Target Recruit Count
- 154
- Registration Number
- NCT06275555
- Locations
- 🇨🇳
Beijing Anzhen Hospital, Beijing, Beijing, China
A Study on the Impact of Bivalirudin Usage During PCI for High-risk Plaques on Post-PCI Coronary Microcirculation.
- Conditions
- Coronary Microvascular Dysfunction
- Interventions
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT05984537
- Locations
- 🇨🇳
Peking university first hospital, Beijing, Beijing, China
BivaLirudin versUS Heparin in Extracorporeal Membrane Oxygenation
- Conditions
- Extracorporeal Membrane Oxygenation Complication
- Interventions
- First Posted Date
- 2023-07-25
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Sydney Local Health District
- Target Recruit Count
- 80
- Registration Number
- NCT05959252
- Locations
- 🇦🇺
Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
Bivalirudin Versus Enoxaparin in Critically Ill COVID-19 Patients
- Conditions
- SARS CoV 2 InfectionAnticoagulantsAcute Respiratory Failure
- Interventions
- First Posted Date
- 2022-04-19
- Last Posted Date
- 2022-08-19
- Lead Sponsor
- University Magna Graecia
- Target Recruit Count
- 58
- Registration Number
- NCT05334654
- Locations
- 🇮🇹
AOU Mater Domini, Catanzaro, Italy
Efficacy and Safety of Bivalirudin Versus Heparin During Coil Embolization in Patients With Ruptured Intracranial Aneurysms
- Conditions
- Subarachnoid Hemorrhage, Aneurysmal
- Interventions
- First Posted Date
- 2020-08-31
- Last Posted Date
- 2020-08-31
- Lead Sponsor
- Changhai Hospital
- Target Recruit Count
- 236
- Registration Number
- NCT04532333
Safety and Efficacy of Bivalirudin During Short-term Intervention of Non-infarction Related Artery After PPCI of STEMI
- Conditions
- STEMI With Multivessel Coronary Disease
- Interventions
- First Posted Date
- 2020-07-17
- Last Posted Date
- 2022-05-02
- Target Recruit Count
- 100
- Registration Number
- NCT04475835
- Locations
- 🇨🇳
First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
Anticoagulation in Patients Suffering From COVID-19 Disease The ANTI-CO Trial
- Conditions
- Anticoagulation in COVID-19 ARDS
- Interventions
- Drug: Standard treatment
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2020-06-24
- Lead Sponsor
- Hamad Medical Corporation
- Target Recruit Count
- 100
- Registration Number
- NCT04445935
- Locations
- 🇶🇦
Hamad Medical Corporation, Doha, Qatar
Multi-center Application of Bivalirudin in Left Atrial Appendage Occlusion
- Conditions
- Evaluate the Safety and Efficacy of Bivalirudin in Decreasing Bleeding Risk
- Interventions
- First Posted Date
- 2019-12-12
- Last Posted Date
- 2019-12-12
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT04195997
- Locations
- 🇨🇳
Zhongshan Hopital of Fudan University, Shanghai, Shanghai, China
Bivalirudin in Late PCI for Oatients With STEMI
- Conditions
- STEMI - ST Elevation Myocardial Infarction
- Interventions
- First Posted Date
- 2019-12-04
- Last Posted Date
- 2019-12-10
- Lead Sponsor
- Second Xiangya Hospital of Central South University
- Target Recruit Count
- 1200
- Registration Number
- NCT04185077
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.